Inactive Instrument

Highlights Sophiris Bio, Inc. Deutsche Boerse AG

Equities

BFF1

CA83578Q2099

Highlights

Unlock all the news: Be the first to know and act before the market!

Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	23/03/16	CI
Sophiris Bio, Inc. Reports Encouraging Preliminary Data from Phase 2A Proof of Concept Study in Localized Prostate Cancer	28/01/16	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	16/11/15	CI
Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint	10/11/15	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	13/08/15	CI
Sophiris Bio, Inc. Enrolls First Patients in Phase 2a Proof of Concept Prostate Cancer Study	26/05/15	CI
Sophiris Bio Inc. Announces Unaudited Consolidated Financial Results for the Three Months Ended March 31, 2015	13/05/15	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Cash Flow Results for the Year Ended December 31, 2014	27/04/15	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014	10/03/15	CI
Sophiris Bio Inc. Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia	18/12/14	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	12/11/14	CI
Sophiris Bio Seeks Acquisitions	16/09/14	CI
Sophiris Bio Reports Completion of Enrollment in the 'PLUS-1' Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia	02/09/14	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	07/08/14	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014	13/05/14	CI
Sophiris Bio, Inc. Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended Dec. 31, 2013	13/03/14	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013	12/11/13	CI
Sophiris Bio, Inc. Announces First Patients Dosed in the 'PLUS-1' Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia	28/10/13	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013	05/08/13	CI
Sophiris Bio, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2013	30/04/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sophiris Bio, Inc. Deutsche Boerse AG

Equities

BFF1

CA83578Q2099

Highlights

Filters